• T. Otto
  • H. Rübben


95% aller Harnblasenkarzinome sind urothelialen Ursprungs und entsprechen histologisch Urothelkarzinomen. 5% der Harnblasentumoren entsprechen Adeno-und Plattenepithelkarzinomen. Die Beschreibung von Tumorausbreitung (TNM) und Differenzierungsgrad (G) der Harnblasentumoren geschieht gemäß den Richtlinien der Internationalen Union gegen den Krebs (UICC).


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bloom HJG, Hendry WF, Wallace DM (1982) Treatment of T3 bladder cancer: controlled trial of preoperative radiotherapy and radical cystectomy versus radical radiotherapy. Second report and review. Brit J Urol 54: 136Google Scholar
  2. 2.
    Boccardo F, Giuliani L et al. (1992) Prophylaxis of superficial bladder carcinoma with MMC or rh-Interfern alpha 2b. Preliminary results of a multicentric Italian study. European Urology (Abstract) 282: 162Google Scholar
  3. 3.
    Bredael JJ, Croker BP, Glenn DF (1980) The curability of invasive bladder cancer treated by radical cystectomy. Eur Urol 6: 206PubMedGoogle Scholar
  4. 4.
    Brendler CB, Schlegel PN, Walsh PC (1990) Urethrectomy with preservation of potency. J Urol 144: 270PubMedGoogle Scholar
  5. 5.
    Debruyne FJG, van der Mejden PM (1987) BCG versus mitomycin C intravesical therapy in patients with superficial bladder cancer: First results of a randomized prospective trial. J Urol 137: 179AGoogle Scholar
  6. 6.
    Eberle J, Wohlgemut M, Bartsch G (1993) Results of combined radio-and chemotherapy for invasive bladder cancer. In pressGoogle Scholar
  7. 7.
    Huland E, Huland H (1989) Local continuous high dose interleukin 2: A new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 49: 5469Google Scholar
  8. 8.
    Khandekar JD, Elson PJ, de Wys WD, Slayton RE, Harris DT (1985) Comparative activity and toxicity of cis-diamminedichloroplatinum ( DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated cell carcinoma of the urinary tract. J Clin Oncol 3: 539Google Scholar
  9. 9.
    Loehrer PJ, Elson P, Kuebler JP, Crawford ED, Tannock I, Raghavan D, Stuart-Harris R, Trump D, Einhorn LH (1990) Advanced bladder cancer. A prospective intergroup trial comparing single agent cisplatin (CDDP) vs M-VAC combination therapy (INT 0078) ( Meeting abstract ). Proc Am Soc Clin Oncol 9: A511Google Scholar
  10. 10.
    Logothetis CJ, Dexeus FH, FinL, Sella A, Amato RI, Ayala AG, Kilboum RG (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8: 1050Google Scholar
  11. 11.
    Logothetis CJ, Hossan B, Sella A, Dexeus FH, Amato RJ (1991) Fluorouracil and recombinant human interferon alpha-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors. J Natl Cancer Inst, 33, 4: 285CrossRefGoogle Scholar
  12. 12.
    Malkowicz SB, Nichols P, Lieskovsky G, Boyd STD, Huffmann J, Skinner DG (1990) The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2). J Urol 144: 641PubMedGoogle Scholar
  13. 13.
    van der Mejden APM, Kurth K-H, Oosterlinck W, Debruyne FMJ, and Members of the EORTC Genito-Urinary Group (1992) Intravesical therapy with Adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group. Cancer Chemother Pharmacol 30 (Suppl): 95–98CrossRefGoogle Scholar
  14. 14.
    Miller LS (1977) Bladder cancer: superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer 39: 973PubMedCrossRefGoogle Scholar
  15. 15.
    Nikima T, Koiso K, Akaqza H (1983) Randomized clinical trial on chemoprophylaxis of recurrences in cases of superficial bladder cancer. Cancer Chemother Pharmacol 11: 79Google Scholar
  16. 16.
    Roehrborn CG, Sagalowsky AJ, Peters PC (1991) Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma of the bladder. J Urol 146: 36PubMedGoogle Scholar
  17. 17.
    RUTT (Registry for Urinary Tract Tumors: Harnwegstumorregister) (1985) Jahresbericht. Verh Dtsch Ges Urol 37: 665Google Scholar
  18. 18.
    Sternberg CN, Yagoda A, Scher HJ, Whitmore WF Jr, Watson RC, Hollander PS, Morse MJ, Herr HW, Sogant PC, Fair WR (1986) Surgical staging and long term survival in patients with advanced transistional cell carcinoma ( TCC) of the urothelium treated with M-VAC. Proc Am Soc Clin Oncol 5: 390Google Scholar
  19. 19.
    Stoter G (1985) Chemotherapy for metastatic bladder carcinoma. J Urol 3: 110Google Scholar
  20. 20.
    Otto T, Rubben H (1994) Management of T1G3 Bladder Carcinomas EBU 3 (16): 122–127Google Scholar
  21. 21.
    Lamm DL (1993) Vitamins in superficial bladder cancer. J Urol (149): 279Google Scholar
  22. 22.
    Igawa M (1994) Simutations of M-VAC Chemotherapy for the treatment of advanced Bladder Carcinoma. J Urol 144: 662Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • T. Otto
  • H. Rübben

There are no affiliations available

Personalised recommendations